# Gregory J. Riely

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gregory-j-riely/

## Facts

| Field | Value |
| --- | --- |
| Citations | 96,841 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 130 |
| i10-index | 355 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5060033755 |
| ORCID iD | 0000-0001-5357-4313 |
| Works | 1,334 |

## Researcher papers

Showing 12 of 46.

- [International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma](https://scholariq.org/papers/international-association-for-the-study-of-lung-cancer-american-thoracic-society/)
- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients](https://scholariq.org/papers/mutational-landscape-of-metastatic-cancer-revealed-from-prospective-clinical/)
- [Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain](https://scholariq.org/papers/acquired-resistance-of-lung-adenocarcinomas-to-gefitinib-or-erlotinib-is/)
- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [OncoKB: A Precision Oncology Knowledge Base](https://scholariq.org/papers/oncokb-a-precision-oncology-knowledge-base/)
- [Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers](https://scholariq.org/papers/analysis-of-tumor-specimens-at-the-time-of-acquired-resistance-to-egfr-tki/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib](https://scholariq.org/papers/i-met-i-amplification-occurs-with-or-without-i-t790m-i-mutations-in-i-egfr-i/)
- [KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib](https://scholariq.org/papers/kras-mutations-and-primary-resistance-of-lung-adenocarcinomas-to-gefitinib-or/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.